Inefficacy of Immunosuppressive Therapy for Severe Aplastic Anemia Progressing From Non-SAA: Improved Outcome After Allogeneic Hematopoietic Stem Cell Transplantation

被引:3
|
作者
Liu, Limin [1 ]
Zhao, Xin [2 ]
Miao, Miao [1 ]
Zhang, Yanming [3 ,4 ]
Jiao, Wenjing [5 ]
Lei, Meiqing [6 ]
Zhou, Huifen [1 ]
Wang, Qingyuan [1 ]
Cai, Yifeng [7 ]
Zhao, Liyun [8 ]
Shangguan, Xiaohui [9 ]
Liu, Zefa [10 ]
Xu, Jinge [11 ]
Zhang, Fengkui [2 ]
Wu, Depei [1 ]
机构
[1] Soochow Univ, Natl Clin Res Ctr Hematol Dis, Jiangsu Inst Hematol, Affiliated Hosp 1, Suzhou, Peoples R China
[2] Chinese Acad Med Sci & Peking Union Med Coll, State Key Lab Expt Hematol, Natl Clin Res Ctr Blood Dis, Anemia Therapeut Ctr,Inst Hematol & Blood Dis Hos, Tianjin, Peoples R China
[3] Xuzhou Med Univ, Dept Hematol, Affiliated Huaian Hosp, Huaian, Peoples R China
[4] Second Peoples Hosp Huaian, Huaian, Peoples R China
[5] Xian Yang Cent Hosp, Dept Hematol, Xianyang, Peoples R China
[6] Cent South Univ, Dept Hematol, Haikou Municipal Peoples Hosp, Affiliated Haikou Hosp,Xiangya Sch Med, Haikou, Hainan, Peoples R China
[7] Nantong Univ, Dept Hematol, Affiliated Hosp, Nantong, Peoples R China
[8] People Hosp Xingtai, Dept Hematol, Xingtai, Peoples R China
[9] Fujian Med Univ, Dept Hematol, Longyan Hosp 1, Longyan, Peoples R China
[10] People Hosp Xinghua, Dept Hematol, Xinghua, Peoples R China
[11] Xuzhou Med Univ, Dept Hematol, Affiliated Hosp 2, Xuzhou, Jiangsu, Peoples R China
来源
FRONTIERS IN ONCOLOGY | 2021年 / 11卷
基金
国家重点研发计划;
关键词
severe aplastic anemia; immunosuppressive therapy; hematopoietic stem cell transplantation; first-line therapy; outcome; BONE-MARROW-TRANSPLANTATION; HIGH-DOSE CYCLOPHOSPHAMIDE; ANTI-THYMOCYTE GLOBULIN; ANTITHYMOCYTE GLOBULIN; POSTTRANSPLANTATION CYCLOPHOSPHAMIDE; CYCLOSPORINE; GUIDELINES; MANAGEMENT; DIAGNOSIS; CHILDREN;
D O I
10.3389/fonc.2021.739561
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background and Aims This study aimed at comparing the efficacy and safety of severe aplastic anemia (SAA) cases that had met the criteria for SAA at the time of diagnosis (group A) with SAA that had progressed from non-SAA (NSAA) (group B), both undergoing first-line immunosuppressive therapy (IST). Additionally, group B was compared with SAA that had progressed from NSAA and who had been treated by allogeneic hematopoietic stem cell transplantation (allo-HSCT) (group C).</p> Methods We retrospectively compared 608 consecutive patients in group A (n = 232), group B (n = 229) and group C (n = 147) between June 2002 and December 2019. Six months after treatment, the rate of overall response and the fraction of patients who had achieved normal blood values, treatment-related mortality (TRM), secondary clonal disease, 5-year overall survival (OS) and failure-free survival (FFS) were indirectly compared between group A and group B, group B and group C.</p> Results Six months after treatment, the rate of overall response and the fraction of patients who had achieved normal blood values in group A was higher than in group B (65.24% vs. 40.54%, P < 0.0001; 23.33% vs. 2.25%, P < 0.0001); the same was true for group C (92.50% vs. 2.25%, P < 0.0001). The rate of relapse in group B was higher than in group C (P < 0.0001), but there were no differences in TRM and secondary clonal disease (P > 0.05). There were no differences in estimated 5-year OS between groups A and B (83.8% +/- 2.6% vs. 85.8% +/- 2.6%, P = 0.837), or between B and C (85.8% +/- 2.6% vs. 77.9% +/- 3.4%, P = 0.051). The estimated 5-year FFS in groups A and C was higher than for group B (57.1% +/- 3.3% vs. 39.7% +/- 3.4%, P < 0.001; 76.7% +/- 3.5% vs. 39.7% +/- 3.4%, P < 0.0001).</p> Conclusion These results indicate that IST is less effective in SAA progressing from non-SAA but allo-HSCT can improve outcomes.</p>
引用
收藏
页数:10
相关论文
共 50 条
  • [31] Comparison of Haploidentical Hematopoietic Stem Cell Transplantation and Immunosuppressive Therapy for the Treatment of Acquired Severe Aplastic Anemia in Pediatric Patients
    Zhang, Yuan
    Guo, Zhi
    Liu, Xiao-Dong
    He, Xue-Peng
    Yang, Kai
    Chen, Peng
    Chen, Hui-Ren
    AMERICAN JOURNAL OF THERAPEUTICS, 2017, 24 (02) : E196 - E201
  • [32] Comparison of hematopoietic stem cell transplantation and immunosuppressive therapy as the first-line treatment option for patients with severe hepatitis-associated aplastic anemia
    Zhang, Xiaoyu
    Yang, Wenrui
    Yang, Donglin
    Wei, Jialin
    Zhang, Ping
    Feng, Sizhou
    Jiang, Erlie
    Zhang, Li
    He, Yi
    Zhang, Fengkui
    Han, Mingzhe
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [33] Mixed Chimerism and Secondary Graft Failure in Allogeneic Hematopoietic Stem Cell Transplantation for Aplastic Anemia
    Kako, Shinichi
    Yamazaki, Hirohito
    Ohashi, Kazuteru
    Ozawa, Yukiyasu
    Ota, Shuichi
    Kanda, Yoshinobu
    Maeda, Tetsuo
    Kato, Jun
    Ishiyama, Ken
    Matsuoka, Ken-ichi
    Miyamoto, Toshihiro
    Iida, Hiroatsu
    Ikegame, Kazuhiro
    Fukuda, Takahiro
    Ichinohe, Tatsuo
    Atsuta, Yoshiko
    Mori, Takehiko
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (03) : 445 - 450
  • [34] Second Allogeneic Hematopoietic Stem Cell Transplantation After Donor Replacement in Children With Severe Aplastic Anemia
    Han, Mojun
    Zhou, Jian
    Zu, Yingling
    Zhang, Yanli
    Gui, Ruirui
    Yu, Fengkuan
    Li, Zhen
    Zhao, Huifang
    Song, Yongping
    TRANSPLANTATION PROCEEDINGS, 2020, 52 (06) : 1860 - 1863
  • [35] Long-term results of allogeneic peripheral blood hematopoietic stem cell transplantation for severe aplastic anemia
    Aladag, Elifcan
    Goker, Hakan
    Demiroglu, Haluk
    Aksu, Salih
    Sayinalp, Nilgun
    Haznedaroglu, Ibrahim Celalettin
    Ozcebe, Osman Ilhami
    Buyukasik, Yahya
    TRANSFUSION AND APHERESIS SCIENCE, 2021, 60 (02)
  • [36] Matched sibling donors versus alternative donors in allogeneic hematopoietic stem cell transplantation for pediatric severe aplastic anemia in Mexico
    Rodriguez, Laura
    Gonzalez-Llano, Oscar
    Villarreal, Laura
    Gomez-Almaguer, David
    Ortiz, Magdalena
    Olaya-Vargas, Alberto
    Perez-Garcia, Martin
    Ruiz-Argueelles, Guillermo J.
    Ruiz-Delgado, Guillermo J.
    Muniz, Teodoro
    De-Diego, Jose
    Reyes, Nancy
    Flores-Villegas, Victoria
    Colunga, Julia
    Sandoval, Adriana
    Gonzalez-Ramella, Oscar
    HEMATOLOGY, 2015, 20 (08) : 449 - 454
  • [37] Comparison of Hematopoietic Stem Cell Transplantation Outcomes Using Matched Sibling Donors, Haploidentical Donors, and Immunosuppressive Therapy for Patients With Acquired Aplastic Anemia
    Zhang, Yuanfeng
    Huo, Jiali
    Liu, Li
    Shen, Yuyan
    Chen, Juan
    Zhang, Tingting
    Chen, Xin
    Pang, Aiming
    Yang, Donglin
    Zhang, Rongli
    Ma, Qiaoling
    Zhai, Weihua
    He, Yi
    Wei, Jialin
    Jiang, Erlie
    Han, Mingzhe
    Zheng, Yizhou
    Feng, Sizhou
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [38] Frontline Therapy Options for Adults With Newly Diagnosed Severe Aplastic Anemia: Intensive immunosuppressive Therapy Plus Eltrombopag or Matched Sibling Donor Hematopoietic Stem Cell Transplantation?
    Huang, Li-fang
    Li, Li
    Jia, Jin-song
    Yang, Yan
    Lin, Sheng-yun
    Meng, Fan-kai
    Zhang, Dong-hua
    He, Guang-sheng
    TRANSPLANTATION AND CELLULAR THERAPY, 2022, 28 (09): : 586.e1 - 586.e7
  • [39] First-line choice for severe aplastic anemia in children: Transplantation from a haploidentical donor vs immunosuppressive therapy
    Cheng, Yifei
    Xu, Zhengli
    Zhang, Yuanyuan
    Wu, Jun
    Wang, Fengrong
    Mo, Xiaodong
    Chen, Yuhong
    Han, Wei
    Jia, Jinsong
    Wang, Yu
    Zhang, Xiaohui
    Huang, Xiaojun
    Zhang, Leping
    Xu, Lanping
    CLINICAL TRANSPLANTATION, 2018, 32 (02)
  • [40] Cord blood infusion-accelerated hematopoietic recovery after combined immunosuppressive therapy with fludarabine and rabbit ATG in severe aplastic anemia
    Jiang, Jieling
    Cai, Yu
    Wan, Liping
    Yang, Jun
    Wang, Chun
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2020, 111 (03) : 360 - 368